Application of ICRP-103 in the calculation of effective dose associated to nuclear medicine tests;Aplicación de los factores de ponderación de la Comisión Internacional de Protección Radiológica 103 en el cálculo de la dosis efectiva asociada a las exploraciones de Medicina Nuclear

Revista Espanola de Medicina Nuclear

Volumn 29, Issue 3, 2010, Pages 114-121

  Pujades Claumarchirant, M C ^a   Marti Vidal J F ^a   Olivas Arroyo, C ^a   Bello Arques P ^a   Mateo Navarro, A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Background equivalent radiation time; Effective dose; Tissue weighting factors

Indexed keywords

INDIUM 111; IODINE 123; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M;

ADULT; AGE; ARTICLE; BODY WEIGHT; BREAST; CHILD; DOSE CALCULATION; DOSE RESPONSE; DOSIMETRY; HUMAN; NUCLEAR MEDICINE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 77952554168     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/S1578-200X(10)70018-8     Document Type: Article

References (16)

1. ICRP Publication 26: Recommendations of the International Commission of Radiological Protection. Ann ICRP 1976, 1.
2. ICRP Publication 60: Recomendaciones 1990, Comisión Internacional de Protección Radiológica. Traducción de la SEPR 1995.
3. ICRP Publication 103: The 2007 recommendations of the International Commission on Radiological Protection. Ann ICRP 2007, 37.
4. ICRP Publication 106: Radiation dose to patients from radiopharmaceuticals: Addendum 3 to ICRP Publication 53. Ann ICRP 2008, 38.
5. ICRP Publication 80: Radiation dose to patients from radiopharmaceuticals, Addendum to ICRP Publication 53. Ann ICRP 1998, 28.
6. ICRP Publication 53: Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1987, 18.
7. Zeng W. Communicating radiation exposure: A simple approach. J Nucl Med Technol 2001, 29:156-158.
8. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources and effects of ionizing radiation. Report to the General Assembly. New York, 2000.
9. Piepsz A., Hahn K., Roca I., Ciofetta G., Toth G., Gordon I., et al. A radiopharmaceutical schedule for imaging in paediatrics. Eur J Nucl Med Mol Imaging 1990, 17:127-129.
10. Hernández A., Millán P.E., Navarrete S., Banzo J. Dosis absorbida de radiación en exploraciones de Medicina Nuclear y riesgos asociados. Rev Esp Med Nucl 1993, 12:13-19.
11. Martin C.J. Effective dose: How should it be applied to medical exposures?. Brt J Radiol 2007, 80:639-647.
12. ICRP Publication 68: Summary of the current ICRP principles for Protection of the Patient in Nuclear Medicine. Supplement Ann ICRP 1994, 24.
13. Bea J., Martí J.F. Dosis impartida al paciente en Medicina Nuclear diagnóstica. Radioprot 1996, 4:18-26.
14. GE Healthcare Bio-Sciences. Nanocoll, kit for radiopharmaceutical preparation, 2009.
15. Amersham Health. DaTSCAN TM 74 MBq/ml solución inyectable, 2003.
16. GE Healthcare.123I-IBZM INJECTION, IOLOPRIDE (123I), 2006.